CapsoVision (CV) Liabilities and Shareholders Equity (2024 - 2025)
CapsoVision (CV) reported Liabilities and Shareholders Equity of $18.2 million for Q4 2025, up 8.1% on a YoY basis from $16.8 million in Q4 2024, and down 29.22% sequentially from $25.7 million in Q3 2025.
CapsoVision (CV) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $18.2 million in Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 8.1% year-over-year to $18.2 million; the trailing twelve-month figure through Dec 2025 stood at $70.2 million (changed N/A YoY), and the FY2025 full-year result was $18.2 million, up 8.1% from the prior year.
- Liabilities and Shareholders Equity retreated to $18.2 million in Q4 2025, from $25.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $25.7 million in Q3 2025 to a low of $9.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn | 18.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.16 Mn |
| Sep 30, 2025 | 25.66 Mn |
| Jun 30, 2025 | 9.55 Mn |
| Dec 31, 2024 | 16.80 Mn |